Letrozole
Primary Brain Tumors
H. Lee Moffitt Cancer Center and Research InstituteSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Primary Brain Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
4-demethyl-4-cholestryloxycarbonylpenclomedine DEKK-TEC, Inc. | Phase 2 | B |
Entrectinib Hoffmann-La Roche | Phase 2 | CCC |
Metformin H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | CC |
Irinotecan H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | CC |
(+)-VINCRISTINE H. Lee Moffitt Cancer Center and Research Institute | Phase 1 | CC |
Same molecule, other indications
Letrozole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →